TY - JOUR T1 -东亚人性别和绝经期睡眠呼吸障碍和代谢共病:Nagahama研究摩根富林明-欧洲呼吸杂志》乔和J - 10.1183/13993003.02251 -2019欧元六世- 56 - 2 SP - 1902251 AU -松本,武盟——Murase Kimihiko盟——Tabara Yasuharu盟——南城,佐藤盟金井,Osamu盟——Takeyama Hirofumi AU -高桥,Naomi AU -岩漠Satoshi盟——Tanizawa Kiminobu盟——Wakamura AU - Komenami,直子非盟- Setoh Kazuya盟,川口Takahisa AU -堤Takanobu盟——盛田Satoshi盟,高桥Yoshimitsu AU - Nakayama, Takeo AU - Hirai, Toyohiro AU - Matsuda, Fumihiko AU - Chin, Kazuo Y1 - 20/08/01 UR - //www.qdcxjkg.com/content/56/2/1902251.abstract N2 -众所周知，在肥胖或代谢合并症患者中，睡眠呼吸障碍(SDB)的患病率增加。然而，根据肥胖的严重程度，SDB患病率与合并症相关的增加方式尚不清楚。这项横断面研究评估了7713名社区参与者使用夜间血氧测量≥2晚。通过腕式活动记录仪(actio - odi3%)测定经睡眠时间校正后的3%氧饱和度指数来评估SDB。SDB严重程度以actio - odi3%定义。肥胖定义为体重指数≥25 kg·m−2。正常、轻度、中度和重度SDB患病率分别为41.0% (95% CI 39.9 ~ 42.1%)、46.9%(45.8 ~ 48.0%)、10.1%(9.5 ~ 10.8%)和2.0%(1.7 ~ 2.3%)，性别差异显著(男性、绝经后女性、绝经前女性)。高血压、糖尿病和代谢综合征等共病与中重度SDB的患病率独立相关，其中任何一种疾病与肥胖的巧合都与中重度SDB的较高概率相关(高血压OR 8.2, 95% CI 6.6-10.2;糖尿病OR 7.8, 95% CI 5.6-10.9; metabolic syndrome OR 6.7, 95% CI 5.2–8.6). Dyslipidaemia in addition to obesity was not additively associated with the prevalence of moderate-to-severe SDB. The number of antihypertensive drugs was associated with SDB (p for trend <0.001). Proportion of a high cumulative percentage of sleep time with oxygen saturation measured by pulse oximetry <90% increased, even among moderate-to-severe SDB with increases in obesity.Metabolic comorbidities contribute to SDB regardless of the degree of obesity. We should recognise the extremely high prevalence of moderate-to-severe SDB in patients with obesity and metabolic comorbidities.Metabolic comorbidities (hypertension, diabetes, dyslipidaemia, metabolic syndrome) contribute to SDB regardless of obesity grade. We should recognise the extremely high prevalence of moderate–severe SDB in patients with obesity and metabolic comorbidities. https://bit.ly/3586fJg ER -